Cytek BiosciencesCTKB +0.11%71 Days Payable is 26.22 as of Mar. 2026, which is 17% above its 10-year median of 22.45. GuruFocus rates CTKB with a GF Score™ of 71/100 and a GF Value™ of $5.82 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Cytek Biosciences ranks worse than 89.81% on this metric.
The historical rank and industry rank for Cytek Biosciences's Days Payable or its related term are showing as below:
CTKB'
s Days Payable Range Over the Past 10 Years
Min: 17.11 Med: 22.45 Max: 29.27
Current: 25.08
During the past 7 years, Cytek Biosciences's highest Days Payable was 29.27. The lowest was 17.11. And the median was 22.45.
CTKB's Days Payable is ranked worse than 89.81% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs CTKB: 25.08
Cytek Biosciences's Days Payable
increased
from Mar. 2025 (25.22) to Mar. 2026 (26.22).
It may suggest that Cytek Biosciencesdelayed paying its suppliers.
Cytek Biosciences Days Payable Related Terms
Cytek Biosciences Days Payable Historical Data
* Premium members only.
The historical data trend for Cytek Biosciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Cytek Biosciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cytek Biosciences Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Cytek Biosciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Cytek Biosciences's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cytek Biosciences (CTKB) has a Days Payable of 26.22 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cytek Biosciences and its competitors. This is 17% above median its historical median of 22.45. Over the past decade, Cytek Biosciences' Days Payable has ranged from 17.11 to 29.27. According to the industry distribution chart, Cytek Biosciences ranks #714 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 89.8%.
Is Cytek Biosciences' Days Payable too high?
Cytek Biosciences' current Days Payable of 26.22 is 17% above median its 10-year median of 22.45. Over the past 10 years, this metric has ranged from a low of 17.11 to a high of 29.27. The Medical Devices & Instruments industry median Days Payable is 67.87. Cytek Biosciences' value of 26.22 is 61.4% below this industry median. Based on the distribution chart, Cytek Biosciences ranks #714 out of 795 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Cytek Biosciences has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cytek Biosciences' Days Payable compare to BBNX and TCMD?
According to the Medical Devices & Instruments industry distribution chart, Cytek Biosciences ranks #714 out of 795 companies for Days Payable. This places Cytek Biosciences in the lower half of its industry. The industry median Days Payable is 67.87. Cytek Biosciences' value of 26.22 is 61.4% below this benchmark. Historically, Cytek Biosciences' own Days Payable has ranged from 17.11 to 29.27 over the past decade. While the company's 10-year median is 22.45 vs. the industry median of 67.87, Cytek Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cytek Biosciences's current Days Payable of 26.22 is 61.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cytek Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cytek Biosciences's current Days Payable is 26.22, which is 17% above median its own 10-year median of 22.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytek Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Cytek Biosciences (CTKB) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.82, compared to a current price of $4.46 — trading 23.4% below its estimated fair value. The current Days Payable is 26.22, which is 17% above median its 10-year median of 22.45 and 61.4% below the Medical Devices & Instruments industry median of 67.87. Cytek Biosciences' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Cytek Biosciences (CTKB), the current Days Payable is 26.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cytek Biosciences (CTKB) Overvalued in 2026?
Based on GuruFocus' analysis, Cytek Biosciences stock appears to be undervalued.
The current stock price of $4.46 is trading 23.4% below its estimated GF Value™ of $5.82.
GuruFocus considers Cytek Biosciences to be Modestly Undervalued.
Key valuation signals for CTKB:
Days Payable: 26.22 (17% above median its 10-year median of 22.45)
GF Value™: $5.82 vs. price of $4.46 (23.4% below fair value)
Industry Position: 61.4% below the Medical Devices & Instruments median (#714 of 795)
No single metric tells the full story. See the CTKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
71GF Score
Get the complete analysis for CTKB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTKB has been successfully added to your 
